LY96 and colorectal carcinoma: After binding to LPS, TLR4-MD2-LPS complex activates the downstream inflammatory cascades through myeloid differentiation primary-response gene 88 (MyD88) and the Toll/IL-1R domain-containing adaptor-inducing interferon β (TRIF) 11, suggesting that targeting MD2 to block the binding of LPS to TLR4 could be a potential pharmacological strategy for CRC treatment.